Anti-HER2 treatment in advanced metastatic HER2-negative breast cancer patients with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells.

被引：0
|
作者：
Kurbacher, Christian M.
Eichler, Christian A.
Quade, Annegret Barbara
Kunstmann, Gerhard
Herz, Susanne
Kurbacher, Jutta Anna
Warm, Mathias R.
机构：
[1] Gynecol Ctr Bonn Friedenspl, Bonn, Germany
[2] Krankenhaus Koln Holweide, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
597
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor
    Beije, Nick
    Onstenk, Wendy
    Kraan, Jaco
    Sieuwerts, Anieta M.
    Hamberg, Paul
    Dirix, Luc Y.
    Brouwer, Anja
    de Jongh, Felix E.
    Jager, Agnes
    Seynaeve, Caroline M.
    Van, Ngoc M.
    Foekens, John A.
    Martens, John W. M.
    Sleijfer, Stefan
    NEOPLASIA, 2016, 18 (11): : 647 - 653
  • [22] Activating HER2 missense mutations in HER2-negative metastatic breast cancer
    Shah, Mirat
    Ensminger, Jennifer
    Wang, Chenguang
    Ali, Siraj
    Chung, Jon
    Lauring, Josh
    Park, Ben Ho
    Stearns, Vered
    CANCER RESEARCH, 2020, 80 (04)
  • [23] Serum HER2 extracellular domain before surgery compared with HER2 in breast cancer
    Zidan, J.
    Mzalbat, R.
    Sharabi, A.
    BREAST, 2015, 24 : S44 - S45
  • [24] Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
    Olson, E. M.
    Flores, L. M.
    Najita, J. S.
    Curley, C.
    Jeong, J.
    Murray, K.
    Savoie, J. J.
    Winer, E. P.
    Krop, I. E.
    CANCER RESEARCH, 2011, 71
  • [25] Her2 expression in matched metastatic tumor and circulating tumor cells (ctcs) in breast cancer: Implications for profiling and monitoring of her2 status to help guide anti-her2 therapy
    Stearns, Vered
    Lehman, Jennifer
    Mitchell, Christine
    Blouw, Barbara
    Huynh, Lan
    Singh, Veena
    CANCER RESEARCH, 2021, 81 (04)
  • [26] HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer
    Mazumder, Aloran
    Shiao, Stephen
    Haricharan, Svasti
    ENDOCRINOLOGY, 2021, 162 (10)
  • [27] A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer
    Yang, Yuqin
    Li, Liudan
    Tian, Wenjing
    Qiao, Zhen
    Qin, Qi
    Su, Liqian
    Li, Peiqiu
    Chen, Weirong
    Zhao, Hong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors
    Wang, Chun
    Mu, Zhaomei
    Ye, Zhong
    Zhang, Zhenchao
    Abu-Khalaf, Maysa M.
    Silver, Daniel P.
    Palazzo, Juan P.
    Jagannathan, Geetha
    Fellin, Frederick M.
    Bhattacharya, Saveri
    Jaslow, Rebecca J.
    Tsangaris, Theodore N.
    Berger, Adam
    Neupane, Manish
    Cescon, Terrence P.
    Lopez, AnaMaria
    Yao, Kaelan
    Chong, Weelic
    Lu, Brian
    Myers, Ronald E.
    Hou, Lifang
    Wei, Qiang
    Li, Bingshan
    Cristofanilli, Massimo
    Yang, Hushan
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (03) : 679 - 689
  • [29] Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors
    Chun Wang
    Zhaomei Mu
    Zhong Ye
    Zhenchao Zhang
    Maysa M. Abu-Khalaf
    Daniel P. Silver
    Juan P. Palazzo
    Geetha Jagannathan
    Frederick M. Fellin
    Saveri Bhattacharya
    Rebecca J. Jaslow
    Theodore N. Tsangaris
    Adam Berger
    Manish Neupane
    Terrence P. Cescon
    AnaMaria Lopez
    Kaelan Yao
    Weelic Chong
    Brian Lu
    Ronald E. Myers
    Lifang Hou
    Qiang Wei
    Bingshan Li
    Massimo Cristofanilli
    Hushan Yang
    Breast Cancer Research and Treatment, 2020, 181 : 679 - 689
  • [30] Role of serum HER2 (sHER2) levels to predict acquisition of HER2 overexpression in patients with metastatic lesions of breast cancer with HER2-negative/unknown at the primary site
    Ribeiro, J. T. M. L.
    Ali, S. M.
    Correia, L.
    Luis, I. M. V. D.
    Matias, M.
    Amaral, T.
    Quintela, A. A. F. G.
    Leitzel, K.
    Lipton, A.
    Costa, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345